文献速递前列腺癌

前列腺癌患者心血管疾病的综合综述:流行病学、危险因素、治疗与预防策略

Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-11-06

本文综述2000至2024年文献,探讨前列腺癌(PC)与心血管疾病(CVD)的相互作用,涉及CVD相关死亡意义、危险因素、雄激素剥夺治疗下CVD加速机制、多种治疗(睾丸切除、紫杉烷化疗、GnRH轴靶向、新一代激素药物和PARP抑制剂)的心脏毒性及预防策略与多学科护理。结论认为CVD是PC男性主要死因,需研究非肿瘤死因及预防策略。

要点

  • CVD是前列腺癌患者的主要死因,生存常由CVD决定。
  • 多种PC治疗(睾丸切除、紫杉烷化疗、GnRH轴靶向、新型激素药物、PARP抑制剂)与心脏毒性相关。
  • 需多学科护理并研究预防策略以改善心血管结局。

核心结论

  • CVD是PC男性的主要死因。
  • 多种新型治疗改善了肿瘤结局,但雄激素轴与CVD之间存在复杂相互作用,可能受现代治疗策略影响。
  • 鉴于PC生存期延长,阐明非肿瘤相关死因并研究预防策略至关重要。

研究设计与样本

  • 全面叙述性综述,在PubMed、Web of Science、ClinicalTrials.gov三个数据库中使用多种检索策略,聚焦2000至2024年发表的文献。

主要发现

  • 综述讨论了CVD相关死亡在PC中的重要性、危险因素及雄激素剥夺背景下CVD加速的潜在机制。
  • 总结了睾丸切除、紫杉烷化疗、GnRH轴靶向、新一代激素药物和PARP抑制剂等治疗的心脏毒性文献。
  • 讨论了预防策略和多学科护理的重要性。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为需要多学科护理并研究预防策略以改善心血管结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of cardiovascular risk factors and disease is high in patients with newly diagnosed prostate cancer (PC). Survivorship of PC patients is often determined by cardiovascular disease (CVD). Our review synthesizes the most recent literature exploring the dynamics between PC and CVD across the disease trajectory and treatments. We review key ongoing clinical trials in the field and highlight avenues for future study. METHODS: We conducted a comprehensive narrative review of the literature using various search strategies in three databases (PubMed, Web of Science, ClinicalTrials.gov), focusing on literature published between 2000 and 2024. RESULTS: We discuss the significance of CVD-related mortality in PC, review the risk factors, and highlight potential mechanisms for accelerated CVD in the androgen-deprivation setting. Furthermore, we summarize key literature of CVD and cardiotoxicity for various therapeutic approaches in PC, including orchiectomy, taxane-based chemotherapy, GnRH-axis targets, and next-generation hormonal agents and PARP inhibitors. Lastly, we discuss prevention strategies and the importance of multi-disciplinary care in this setting. CONCLUSION: CVD is a major cause of death in men with PC. Various novel therapeutic approaches have been pivotal in improving oncologic outcomes, but emerging data demonstrate a complex interplay between the androgen axis and CVD that is likely affected by modern treatment strategies. Given the prolonged PC survivorship, unraveling non-oncologic related causes of death and investigating prevention strategies are imperative (Fig. 1). Fig. 1 LANDSCAPE OF PROSTATE CANCER.: Spectrum of prostate cancer disease states (red) and interventions (yellow) with the potential role for optimization (green) to improve cardiovascular outcomes in the future (blue).

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Moryousef J, Duivenvoorden W, Leong D, et al. Comprehensive review of cardiovascular disease in prostate cancer: epidemiology, risk factors, therapeutics and prevention strategies. Prostate Cancer Prostatic Dis. 2024. PMID: 39506079. doi:10.1038/s41391-024-00897-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。